Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

<ul>
<li>Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>In this note, we will talk about the company’s past performance and future prospects.</li>
</ul>


Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
In this note, we will talk about the company’s past performance and future prospects.


2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/giant-biogene-holding-co-ltd" target="_blank" data-smartkarma-citation="entities:35950:1" rel="noopener">Giant Biogene (2367 HK)</a> aims to raise up to US$205m via a top-up placement.</li>
<li>We have followed the company since listing and its recent performance has been great. Although it doesn’t seem to need the cash.</li>
<li>In this note, we will run the deal through our ECM framework and talk about the recent updates.</li>
</ul>



Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement.
We have followed the company since listing and its recent performance has been great. Although it doesn’t seem to need the cash.
In this note, we will run the deal through our ECM framework and talk about the recent updates.


Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Tingyi is a dominant force in China's consumer staples sector, holding a leading market share in both instant noodles and ready-to-drink (RTD) tea with its powerful 'Master Kong' brand.</li>
  <li>Despite a recent trend of slightly declining revenues, the company has demonstrated strong bottom-line growth, driven by favorable raw material costs, price adjustments, and operational efficiencies that have significantly expanded profit margins.</li>
  <li>The company faces intense competition and shifting consumer preferences towards healthier options, but its strategic focus on product premiumization, channel diversification, and a strong dividend payout policy positions it to navigate future challenges.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Tingyi is a dominant force in China's consumer staples sector, holding a leading market share in both instant noodles and ready-to-drink (RTD) tea with its powerful 'Master Kong' brand.
  Despite a recent trend of slightly declining revenues, the company has demonstrated strong bottom-line growth, driven by favorable raw material costs, price adjustments, and operational efficiencies that have significantly expanded profit margins.
  The company faces intense competition and shifting consumer preferences towards healthier options, but its strategic focus on product premiumization, channel diversification, and a strong dividend payout policy positions it to navigate future challenges.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Tingyi Holding (322 HK) - Apr 2026

HK/China Equity Long-Short

Osbert Tang, CFA

Thematic (Sector/Industry)

<ul>
<li>The elevated crude oil prices are expected to drive persistent inflationary pressure, and this will benefit high dividend yield stocks.</li>
<li>The top 10 high-yield HSI constituents have an average dividend yield of 6.7% for CY26. Since the War, they have outperformed the Index by an average of 1.1pp.</li>
<li>
<a href="https://www.smartkarma.com/entities/china-unicom-hong-kong-ltd" target="_blank" data-smartkarma-citation="entities:1016:1" rel="noopener">China Unicom HK (762 HK)</a>, <a href="https://www.smartkarma.com/entities/china-mobile-ltd" target="_blank" data-smartkarma-citation="entities:27:1" rel="noopener">China Mobile (941 HK)</a>, <a href="https://www.smartkarma.com/entities/link-reit" target="_blank" data-smartkarma-citation="entities:872:1" rel="noopener">Link REIT (823 HK)</a>, <a href="https://www.smartkarma.com/entities/tingyi-cayman-islands-holding-corp" target="_blank" data-smartkarma-citation="entities:14016:1" rel="noopener">Tingyi Holding (322 HK)</a>, and <a href="https://www.smartkarma.com/entities/china-hongqiao-group-ltd" target="_blank" data-smartkarma-citation="entities:1909:1" rel="noopener">China Hongqiao (1378 HK)</a> are at the top of the list.</li>
</ul>


The elevated crude oil prices are expected to drive persistent inflationary pressure, and this will benefit high dividend yield stocks.
The top 10 high-yield HSI constituents have an average dividend yield of 6.7% for CY26. Since the War, they have outperformed the Index by an average of 1.1pp.

China Unicom HK (762 HK), China Mobile (941 HK), Link REIT (823 HK), Tingyi Holding (322 HK), and China Hongqiao (1378 HK) are at the top of the list.


HK Strategy: Winners of Potentially Higher Inflation

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our global (MSCI ACWI) near-term outlook to neutral in our 3/17/26 Int'l Macro Vision, following ACWI-US breaking below $141.50 support.</li>
<li>The bottom line is that we do not see the S&amp;P 500 (SPX) or MSCI ACWI breaking out to new highs –at least not until we see more downside first.</li>
<li>The growing list of concerns that we have discussed since early-February remains a problem for global equities. Crucial <a href="https://www.smartkarma.com/entities/ishares-msci-acwi-etf" target="_blank" data-smartkarma-citation="entities:24402:1" rel="noopener">iShares MSCI ACWI ETF (ACWI US)</a>  support at $134-$135.70 testing now.</li>
</ul>


We downgraded our global (MSCI ACWI) near-term outlook to neutral in our 3/17/26 Int'l Macro Vision, following ACWI-US breaking below $141.50 support.
The bottom line is that we do not see the S&amp;P 500 (SPX) or MSCI ACWI breaking out to new highs –at least not until we see more downside first.
The growing list of concerns that we have discussed since early-February remains a problem for global equities. Crucial iShares MSCI ACWI ETF (ACWI US)  support at $134-$135.70 testing now.


Stay Defensive. Buys in Global Energy, Materials, Transports, Communications, Utilities, Staples

China

Tingyi is a major Chinese packaged food and beverage company that manufactures and sells instant noodles, ready-to-drink teas, juices, bottled water, and other instant food products under its Master Kong brand. It also engages in property investment and logistics. The company was founded in 1992 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tingyi (322 HK)

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash

Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through...

Sumeet Singh

Primer: Tingyi Holding (322 HK) - Apr 2026

Tingyi is a dominant force in China's consumer staples sector, holding a leading market share in both instant noodles and ready-to-drink (RTD)...

αSK Primers

HK Strategy: Winners of Potentially Higher Inflation

Elevated crude oil prices are driving inflation, benefiting high dividend yield HSI constituent stocks like China Unicom, China Mobile, Link REIT,...

Osbert Tang, CFA

Stay Defensive. Buys in Global Energy, Materials, Transports, Communications, Utilities, Staples

Thursday's International Compass: Stay Defensive. Actionable Global Sectors: Energy, Materials, Transportation, Communications, Utilities, and...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash

Giant Biogene (2367 HK) aims to raise up to US$205m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through...

Sumeet Singh

Primer: Tingyi Holding (322 HK) - Apr 2026

Tingyi is a dominant force in China's consumer staples sector, holding a leading market share in both instant noodles and ready-to-drink (RTD)...

αSK Primers

HK Strategy: Winners of Potentially Higher Inflation

​Elevated crude oil prices are driving inflation, benefiting high dividend yield HSI constituent stocks like China Unicom, China Mobile, Link REIT,...

Osbert Tang, CFA

Stay Defensive. Buys in Global Energy, Materials, Transports, Communications, Utilities, Staples

Thursday's International Compass: Stay Defensive. Actionable Global Sectors: Energy, Materials, Transportation, Communications, Utilities, and...

Vermilion Research

Elevated crude oil prices are driving inflation, benefiting high dividend yield HSI constituent stocks like China Unicom, China Mobile, Link REIT,...